Non-Prescription Mevacor ® Merck & Co., Inc. New Drug Application 21-213 Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committee.

Slides:



Advertisements
Similar presentations
Julianne Gee, MPH Immunization Safety Office
Advertisements

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.
Clinical question: When do you get statin induced myopathy?
Data Mining in VAERS to Enhance Vaccine Safety Monitoring at the FDA
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Summary of Drug Abuse “Rates” in the United States: Focus on Morphine Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and.
1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,
EPIB-591 Screening Jean-François Boivin 29 September
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)
Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
Risk of colorectal cancer in patients taking statins and NSAIDS Dr Yana Vinogradova, Prof Julia Hippisley-Cox, Dr Carol Coupland and Prof Richard Logan.
DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.
How to Analyze Therapy in the Medical Literature (part 2)
Pharmacoeconomics and Outcomes Research Dean G. Smith, Ph.D. October 10, 2005 UM Student Chapter.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:
Anti-Infective Drugs Advisory Committee Meeting December 15, Data Mining Analysis of Multiple Antibiotics in AERS Jonathan G. Levine, PhD Mathematical.
1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.
? OTC LOVASTATIN Jesse M. Polansky M.D., M.P.H. Representing self.
Lecture 7 Objective 18. Describe the elements of design of observational studies: case ‑ control studies (retrospective studies). Discuss the advantages.
1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.
Center for Drug Evaluation and Research Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,
VSM CHAPTER 6: HARM Evidence-Based Medicine How to Practice and Teach EMB.
CI-1 CRESTOR ® (rosuvastatin calcium) Tablets Endocrinologic and Metabolic Drugs Advisory Committee Bethesda, Maryland July 9, 2003 C.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
Amyotrophic Lateral Sclerosis. Motor Neuron Disease Terminology Lower motor neuron Upper motor neuron Progressive Muscular Atrophy Amyotrophic Lateral.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Tysabri ® (natalizumab) Biogen Idec Inc. BLA /15 Peripheral and Central Nervous System Drugs Advisory Committee Gaithersburg, Maryland March 7-8,
Statin Induce Myotoxicity
Endocrinologic & Metabolic Drugs Advisory Committee Meeting
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Background Objectives Results Methods Within State Geographic Variation in Antipsychotic Medication Treatment for Medicaid-insured Children and Adolescents.
1 ADHD drugs and CV outcomes: Preliminary feasibility results and potential observational studies David J. Graham, MD, MPH on behalf of the FDA Epidemiology.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Good Pharmacovigilance Practices
Update on the febrile seizure signal after influenza vaccine David Martin, MD, MPH Pharmacovigilance Branch Division of Epidemiology Office of.
Teriparatide or LY Eli Lilly & Company NDA Metabolic-Endocrine Drugs Metabolic-Endocrine Drugs Advisory Committee Advisory Committee Bethesda,
Signal identification and development I.Ralph Edwards.
OTC NSAID and ASA GI Bleeding Analysis of Spontaneous Reports Nonprescription Drugs Advisory Committee Meeting Joyce P. Weaver, Pharm.D. Office of Drug.
1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
ISOTRETINOIN RISK MANAGEMENT PROGRAM Background Information Genpharm Inc. Mylan/Bertek Pharmaceuticals Inc. Barr Laboratories, Inc. Ranbaxy Pharmaceuticals.
Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.
Active Surveillance Using Longitudinal Data: A Pilot Project Drug Safety and Risk Management Advisory Committee Meeting Silver Spring, Maryland May 18,
Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.
Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.
1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.
1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.
1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial J Am Coll Cardiol 2007;50:291-5 Jacqueline Saw, MD*, Danielle Brennan, MS†,
8. Causality assessment:
ASPIRE Workshop 5: Application of Biostatistics
ASPIRE Workshop 5: Application of Biostatistics
ACIP Feb , 2007 Guillain-Barré Syndrome (GBS) Among Recipients of Meningococcal Conjugate Vaccine (MCV4,Menactra®) Update Oct Jan Robert.
Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.
ASPIRE Workshop 5: Application of Biostatistics
Presentation transcript:

Non-Prescription Mevacor ® Merck & Co., Inc. New Drug Application Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committee Meeting Silver Spring, Maryland December 13, 2007 Eric Colman, MD Division of Metabolism and Endocrinology Products Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committee Meeting Silver Spring, Maryland December 13, 2007 Eric Colman, MD Division of Metabolism and Endocrinology Products Center for Drug Evaluation and Research

FDA Advisory Committee Meeting December 13, ObjectiveObjective To discuss FDA’s evaluation of data mining signals for amyotrophic lateral sclerosis (ALS) with statins Background ALS What is data mining? FDA data mining signal scores for ALS with statins FDA’s evaluation of the data mining signals Next steps To discuss FDA’s evaluation of data mining signals for amyotrophic lateral sclerosis (ALS) with statins Background ALS What is data mining? FDA data mining signal scores for ALS with statins FDA’s evaluation of the data mining signals Next steps

FDA Advisory Committee Meeting December 13, FDA Observes Data Mining Signal for ALS with Statins Earlier this year members from numerous offices and divisions within the Center for Drug Evaluation and Research met to discuss data mining signals for ALS and statins observed in FDA’s Adverse Event Reporting System (AERS) Available data did not justify regulatory action Make evaluation publicly available –Manuscript in progress Earlier this year members from numerous offices and divisions within the Center for Drug Evaluation and Research met to discuss data mining signals for ALS and statins observed in FDA’s Adverse Event Reporting System (AERS) Available data did not justify regulatory action Make evaluation publicly available –Manuscript in progress

FDA Advisory Committee Meeting December 13, Edwards, et al. Drug Safety June, 2007

FDA Advisory Committee Meeting December 13, Edwards, et al. “…….we hope that this signal [for an ALS-like syndrome with statins] will be accepted not as anything more than a hypothesis that needs to be followed up to ensure the safer use of an important group of medicines.”

FDA Advisory Committee Meeting December 13, Wall Street Journal July, 2007

FDA Advisory Committee Meeting December 13, Amyotrophic Lateral Sclerosis Progressive destruction of motor neurons with retraction of axons from neuromuscular junction Often presents with muscle weakness Annual incidence 1.5 to 2 cases per 100,000 Incidence increases with age Males > females Etiology unknown Progressive destruction of motor neurons with retraction of axons from neuromuscular junction Often presents with muscle weakness Annual incidence 1.5 to 2 cases per 100,000 Incidence increases with age Males > females Etiology unknown

FDA Advisory Committee Meeting December 13, Drug Safety Data Mining Definition: the use of computer algorithms to analyze adverse event data in a large, complex database –FDA’s Adverse Event Reporting System (AERS) –Spontaneously-submitted adverse events from healthcare professionals, consumers, and drug companies Goal: to identify reporting relationships that could signal possible adverse drug reactions Data mining CAN: generate hypotheses regarding adverse drug reactions Data mining CANNOT: prove or refute causal associations between drugs and adverse reactions Definition: the use of computer algorithms to analyze adverse event data in a large, complex database –FDA’s Adverse Event Reporting System (AERS) –Spontaneously-submitted adverse events from healthcare professionals, consumers, and drug companies Goal: to identify reporting relationships that could signal possible adverse drug reactions Data mining CAN: generate hypotheses regarding adverse drug reactions Data mining CANNOT: prove or refute causal associations between drugs and adverse reactions

FDA Advisory Committee Meeting December 13, Proportional Reporting Ratios Observed/Expected a/(a+b)/c/(c+d) Reports With Adverse Event Y Reports Without Adverse Event Y Drug Xaba+b All Other Drugscdc+d a+cb+dtotal

FDA Advisory Committee Meeting December 13, ExampleExample Reports With Pancreatitis Reports Without Pancreatitis Lipovent / All Other Drugs In AERS / Observed ratio of pancreatitis reports for Lipovent: 10/ = Expected ratio of pancreatitis reports for Lipovent: 3/ = Proportional reporting ratio = 0.048/0.001 = 48

FDA Advisory Committee Meeting December 13, Data Mining Terminology EBGM is the Empirical Bayes Geometric Mean - an adjusted estimate of the mean proportional reporting ratio that addresses small cell counts –EB05 = lower bound of confidence interval –EB95 = upper bound of confidence interval EBGM is the Empirical Bayes Geometric Mean - an adjusted estimate of the mean proportional reporting ratio that addresses small cell counts –EB05 = lower bound of confidence interval –EB95 = upper bound of confidence interval

FDA Advisory Committee Meeting December 13, What Constitutes a Data Mining Signal? Criteria not written in stone EB05 > 2 EBGM > 2 Consider the whole range of scores for new drugs or very serious outcomes Criteria not written in stone EB05 > 2 EBGM > 2 Consider the whole range of scores for new drugs or very serious outcomes

FDA Advisory Committee Meeting December 13, FDA Data Mining Signal Scores for Statins and ALS IngredientEBGMEB05EB95 Pravastatin Fluvastatin Atorvastatin Cerivastatin Lovastatin Simvastatin Rosuvastatin EBGM is not an odds ratio or a measure of relative or absolute risk EBGM is not a causality score

FDA Advisory Committee Meeting December 13, What Did FDA Do In Response to the Data Mining Signals for ALS and Statins? Reviewed: –AERS reports of ALS –Statin clinical trial data –Population-based ALS incidence data Reviewed: –AERS reports of ALS –Statin clinical trial data –Population-based ALS incidence data

FDA Advisory Committee Meeting December 13, Review of AERS Reports of ALS All reports reviewed by a safety evaluator and two neurologists 57 domestic reports Mean age 67 years –39% 70 – 79 years old 53% male Clinical course after statin D/C’d –84% no improvement –2% improved –14% unknown Most reports received by FDA during or after 2000 Initial Reporter Source –53% non-healthcare consumer –33% physician –11% non-physician healthcare provider All reports reviewed by a safety evaluator and two neurologists 57 domestic reports Mean age 67 years –39% 70 – 79 years old 53% male Clinical course after statin D/C’d –84% no improvement –2% improved –14% unknown Most reports received by FDA during or after 2000 Initial Reporter Source –53% non-healthcare consumer –33% physician –11% non-physician healthcare provider

FDA Advisory Committee Meeting December 13, Retrospective Analyses of Statin Clinical Trials 42 placebo-controlled trials of all marketed statins 6 months to 5 years in duration Primary and secondary CAD prevention 200,000 person-years statin exposure 200,000 person-years placebo exposure 9 cases of ALS in statin groups 9 cases of ALS in placebo groups –4.3 cases per 100,000 vs. 4.6 cases per 100, placebo-controlled trials of all marketed statins 6 months to 5 years in duration Primary and secondary CAD prevention 200,000 person-years statin exposure 200,000 person-years placebo exposure 9 cases of ALS in statin groups 9 cases of ALS in placebo groups –4.3 cases per 100,000 vs. 4.6 cases per 100,000

FDA Advisory Committee Meeting December 13, Statin Use – ALS Incidence Use of statins has increased steadily since early 1990s Has the incidence of ALS increased? Data from Rochester, MN –Before 1990: 1.5 cases per 100,000 people per year (1.1 to 2.0) –After 1990: 1.9 cases per 100,000 people per year (1.0 to 2.8) Sorenson EJ, et al. Neurology. 2002;59(2): Dispensed prescriptions by US retail pharmacies. Verispan Vector One; National, Years , Extracted October 2007

FDA Advisory Committee Meeting December 13, What Should We Make of the Data Mining Signals? What Should We Make of the Data Mining Signals? No imbalance in ALS from placebo-controlled statin trials No dramatic increase in the incidence of ALS despite dramatic increase in the use of statins Could statins unmask or exacerbate muscle symptoms of ALS? Could the data mining signals be the result of reporting bias? No imbalance in ALS from placebo-controlled statin trials No dramatic increase in the incidence of ALS despite dramatic increase in the use of statins Could statins unmask or exacerbate muscle symptoms of ALS? Could the data mining signals be the result of reporting bias?

FDA Advisory Committee Meeting December 13, Reporting Biases A major concern with all spontaneous reporting databases Both statins and ALS associated with muscle symptoms Detected a data mining signal for ALS with fenofibrate, another lipid-altering drug associated with myopathy Detected data mining signals for dermatomyositis and polymyositis with statins A major concern with all spontaneous reporting databases Both statins and ALS associated with muscle symptoms Detected a data mining signal for ALS with fenofibrate, another lipid-altering drug associated with myopathy Detected data mining signals for dermatomyositis and polymyositis with statins

FDA Advisory Committee Meeting December 13, Next Steps Ongoing case-control study Kaiser Permanente Northern California Lorene Nelson, PhD, Stanford University School of Medicine is the Principal Investigator Questions addressed: –Does the use of cholesterol-lowering drugs increase the risk of developing ALS? –Is the use of cholesterol-lowering drugs associated with the length of survival after diagnosis among subjects with ALS? –Is there a relationship between cholesterol levels prior to disease onset and the risk of developing ALS, independent of the use of cholesterol lowering agents? Study should be completed in mid-to-late 2008 Ongoing case-control study Kaiser Permanente Northern California Lorene Nelson, PhD, Stanford University School of Medicine is the Principal Investigator Questions addressed: –Does the use of cholesterol-lowering drugs increase the risk of developing ALS? –Is the use of cholesterol-lowering drugs associated with the length of survival after diagnosis among subjects with ALS? –Is there a relationship between cholesterol levels prior to disease onset and the risk of developing ALS, independent of the use of cholesterol lowering agents? Study should be completed in mid-to-late 2008

FDA Advisory Committee Meeting December 13, ColleaguesColleagues Ana Szarfman, MD, PhD Andy Mosholder, MD, MPH Devanand Jillapalli, MD Jay Levine, PhD Jo Wyeth, PharmD Mark Avigan, MD, CM Joe Tonning, MD, MPH Rita Ouellet-Hellstrom, PhD, MPH Allen Brinker, MD, MPH Ana Szarfman, MD, PhD Andy Mosholder, MD, MPH Devanand Jillapalli, MD Jay Levine, PhD Jo Wyeth, PharmD Mark Avigan, MD, CM Joe Tonning, MD, MPH Rita Ouellet-Hellstrom, PhD, MPH Allen Brinker, MD, MPH